How will HPV vaccines affect cervical cancer?

被引：211

作者：

Roden, Richard ^{[1
]}

Wu, T. -C.

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA

[2] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA

[3] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD 21231 USA

[4] Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD 21231 USA

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 10期

关键词：

D O I：

10.1038/nrc1973

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with `high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.

引用

页码：753 / 763

页数：11